News
Sensorion to Present New Data on OTOF Gene Therapy at the Association for Research in Otolaryngology ARO 45th Annual MidWinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Median Technologies Announces 2021 Revenue of €20.5 Million, Up 52%, and a Strengthened Cash Position of €39 Million
Regulatory News:
Median Technologies (ALMDT:PA) today announces its business activity indicators for the full year 2021. In 2021, the company’s business continued to grow at a rapid pace.
Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Valbiotis: entscheidende Phase mit Studiendaten für wichtige Indikationen – für 2022 werden Ergebnisse für Prädiabetes, Hypercholesterinämie und Bluthochdruck erwartet
Pflichtmitteilung:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Median Technologies Announces Outstanding Lung Nodule Detection (CADe1) Performance for iBiopsy® Lung Cancer Screening
Regulatory News:
Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy® Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.
Median Technologies: Financial Communications Schedule for the First Half of 2022
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA), announces the publication date for its 2021 results:
Publication
Date
2021 results
April 26, 2022*
Sensorion appoints Aniz Girach as Independent Board Member
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that the
Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
BIOCORP vereinbart neue Partnerschaft mit H&T über InspairTM
Aufsichtsrechtliche Meldungen:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA-PME), ein französisches Unternehmen, das sich auf die Konzeption, Entwicklung und Herstellung innovativer
BIOCORP Signs New Partnership Around InspairTM With H&T Presspart
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for
Valbiotis meldet die Einreichung von drei klinischen Protokollen für den zur Blutdrucksenkung indizierten Wirkstoff TOTUM•854 bei den zuständigen Behörden und stellt seinen Plan für eine umfassende klinische Entwicklung vor
Pflichtmeldung:
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert) (Paris:AVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:AVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
ROCTOOL: Yearly results 2021 - Strong acceleration of activity: +27%
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
BILENDI: Bilendi surpasses 2023 revenue target 2 years ahead of schedule and changes dimension
SPAC: Strategic Turnaround - Entry into Exclusive Negotiations to Acquire an Artificial Intelligence (AI) Hotel Reservation Platform